Who are Soluble beta-glucan (SBG)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OM-85 BV, Levagen+, Imiquimod and Interferon alpha, Poly IC, Mistletoe extract, Bacterial Lysates.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/soluble-beta-glucan-sbg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Soluble beta-glucan (SBG) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Soluble beta-glucan (SBG) (Soluble beta-glucan (SBG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunostimulant. Area: Immunology.

phase 3 Immunostimulant Dectin-1, Complement Receptor 3 (CR3) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Soluble beta-glucan (SBG) (Soluble beta-glucan (SBG)) — Biotec Pharmacon ASA. Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Soluble beta-glucan (SBG) TARGET	Soluble beta-glucan (SBG)	Biotec Pharmacon ASA	phase 3	Immunostimulant	Dectin-1, Complement Receptor 3 (CR3)
OM-85 BV	OM-85 BV	Chinese Academy of Medical Sciences	marketed	Bacterial lysate immunostimulant
Levagen+	Levagen+	RDC Clinical Pty Ltd	marketed	Immunostimulant	Immune cell activation (non-specific)
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
Poly IC	Poly IC	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	TLR3 agonist / Immunostimulant	TLR3 (Toll-like receptor 3)
Mistletoe extract	Mistletoe extract	Rambam Health Care Campus	marketed	Botanical immunostimulant
Bacterial Lysates	Bacterial Lysates	Sanofi	marketed	Immunostimulant; bacterial lysate

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunostimulant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Biotec Pharmacon ASA · 1 drug in this class
RDC Clinical Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Soluble beta-glucan (SBG) — Competitive Intelligence Brief. https://druglandscape.com/ci/soluble-beta-glucan-sbg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab